Dinesh V Ph D Patel Protagonist Therapeutics, Inc (PTGX) insider trading activity

PTGX Quotes by TradingView

Dinesh V Ph D Patel is President and CEO of Protagonist Therapeutics, Inc. Currently has a direct ownership of 408,455 shares of PTGX, which is worth approximately $16.1 Million. The most recent transaction as insider was on Nov 26, 2024, when has been sold 21,480 shares (Common Stock) at a price of $46.25 per share, resulting in proceeds of $993,450. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 408K
20.6% 3M change
23.56% 12M change
Total Value Held $16.1 Million

DINESH V PH D PATEL Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 26 2024
SELL
Open market or private sale
$993,450 $46.25 p/Share
21,480 Reduced 5.0%
408,455 Common Stock
Nov 25 2024
SELL
Bona fide gift
-
7,000 Reduced 1.61%
428,208 Common Stock
Nov 25 2024
SELL
Open market or private sale
$3,687,299 $46.96 p/Share
78,520 Reduced 15.28%
435,208 Common Stock
Nov 25 2024
BUY
Exercise of conversion of derivative security
$37,268 $21.58 p/Share
1,727 Added 0.4%
429,935 Common Stock
Nov 19 2024
SELL
Bona fide gift
-
1,000 Reduced 0.19%
513,415 Common Stock
Jun 13 2024
SELL
Bona fide gift
-
1,000 Reduced 0.19%
514,415 Common Stock
Jun 07 2024
SELL
Open market or private sale
$1,231,650 $35.19 p/Share
35,000 Reduced 6.36%
515,415 Common Stock
Apr 01 2024
SELL
Open market or private sale
$707,750 $28.31 p/Share
25,000 Reduced 4.35%
549,590 Common Stock
Mar 01 2024
SELL
Open market or private sale
$948,600 $31.62 p/Share
30,000 Reduced 4.96%
574,590 Common Stock
Feb 26 2024
SELL
Payment of exercise price or tax liability
$322,319 $29.53 p/Share
10,915 Reduced 1.77%
604,590 Common Stock
Feb 15 2024
SELL
Payment of exercise price or tax liability
$104,930 $28.23 p/Share
3,717 Reduced 0.6%
615,505 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
-
84,875 Added 12.05%
619,222 Common Stock
Dec 13 2023
SELL
Open market or private sale
$1,505,999 $20.08 p/Share
75,000 Reduced 12.31%
534,347 Common Stock
Oct 18 2023
BUY
Exercise of conversion of derivative security
$25,260 $4.21 p/Share
6,000 Added 0.98%
609,347 Common Stock
May 31 2023
SELL
Payment of exercise price or tax liability
$317,141 $26.07 p/Share
12,165 Reduced 1.98%
602,946 Common Stock
May 31 2023
BUY
Grant, award, or other acquisition
-
30,000 Added 4.65%
615,111 Common Stock
Feb 22 2023
SELL
Bona fide gift
-
10,000 Reduced 1.69%
583,448 Common Stock
Dec 28 2022
SELL
Bona fide gift
-
3,116 Reduced 0.52%
598,096 Common Stock
Aug 23 2022
BUY
Exercise of conversion of derivative security
$84,200 $4.21 p/Share
20,000 Added 3.2%
604,048 Common Stock
May 04 2022
SELL
Bona fide gift
-
3,000 Reduced 0.51%
581,048 Common Stock
May 04 2022
BUY
Exercise of conversion of derivative security
$66,274 $4.21 p/Share
15,742 Added 2.62%
584,048 Common Stock
Apr 26 2022
BUY
Exercise of conversion of derivative security
$126,300 $4.21 p/Share
30,000 Added 5.01%
568,306 Common Stock
Apr 14 2022
BUY
Exercise of conversion of derivative security
$64,424 $1.89 p/Share
34,087 Added 5.96%
537,847 Common Stock
Feb 28 2022
SELL
Payment of exercise price or tax liability
$112,853 $24.28 p/Share
4,648 Reduced 0.91%
503,760 Common Stock
Feb 15 2022
BUY
Grant, award, or other acquisition
-
31,250 Added 5.79%
508,408 Common Stock
DVP

Dinesh V Ph D Patel

President and CEO
Newark, CA

Track Institutional and Insider Activities on PTGX

Follow Protagonist Therapeutics, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

News

Receive news related to Protagonist Therapeutics, Inc

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on PTGX